文献速递造血干细胞移植与细胞治疗白血病淋巴瘤

儿童血液系统恶性肿瘤第二次单倍体造血干细胞移植采用TCRαβ/CD19去除或移植后环磷酰胺的结局比较

Outcomes of children with haematological malignancies given second haploidentical haematopoietic stem cell transplantation with either TCRαβ/CD19 depletion or post-transplant cyclophosphamide.
PubMed 文献 · Br J Haematol · 2025-07-21

这项回顾性多中心研究分析了123例接受第二次单倍体造血干细胞移植的儿童血液系统恶性肿瘤患者,其中56例采用移植后环磷酰胺(PTCy),67例采用TCRαβ/CD19去除。两组24个月总生存率和无事件生存率无显著差异,但PTCy组急性及慢性移植物抗宿主病累积发生率更高,而TCRαβ组腺病毒再激活率更高。

要点

  • 第二次单倍体移植后,PTCy与TCRαβ去除的24个月总生存率和无事件生存率无显著差异。
  • PTCy组100天任何级别急性GVHD及24个月慢性GVHD累积发生率均高于TCRαβ组。
  • TCRαβ组腺病毒再激活率高于PTCy组,其余感染并发症相当。

核心结论

  • 在第二次单倍体造血干细胞移植中,PTCy与TCRαβ去除提供相当的临床结局,但PTCy与更高的GVHD发生率相关,而TCRαβ去除与更高的腺病毒再激活率相关。

研究设计与样本

  • 回顾性多中心研究,纳入123例接受第二次单倍体造血干细胞移植的儿童血液系统恶性肿瘤患者,56例接受PTCy,67例接受TCRαβ去除。

主要发现

  • 24个月总生存率PTCy组56.8%(95%CI:42.5%-71.1%) vs TCRαβ组43.2%(95%CI:31.4%-55.1%),无显著差异。
  • 24个月无事件生存率PTCy组44.1%(95%CI:30.3%-57.8%) vs TCRαβ组35.8%(95%CI:24.3%-47.3%),无显著差异。
  • 累积复发率PTCy组34.0%(95%CI:23.1%-50.1%) vs TCRαβ组37.3%(95%CI:27.3%-50.8%),p=0.28;非复发死亡率PTCy组18.9%(95%CI:10.7%-33.4%) vs TCRαβ组25.3%(95%CI:16.8%-38.2%),p=0.48。
  • 100天任何级别急性GVHD累积发生率PTCy组55.3%(95%CI:43.7%-70.4%) vs TCRαβ组32.8%(95%CI:23.3%-46.2%),p=0.02;II-IV级和III-IV级差异无统计学意义。
  • 24个月慢性GVHD累积发生率PTCy组38.8%(95%CI:27.6%-54.6%) vs TCRαβ组11.9%(95%CI:6.2%-22.8%),p<0.01;中重度慢性GVHD PTCy组15.3%(95%CI:8.1%-29.1%) vs TCRαβ组1.4%(95%CI:0.2%-10.4%),p<0.01。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Human leukocyte antigen (HLA)-haploidentical haematopoietic cell transplantation (haplo-HCT) is a suitable salvage strategy in children with haematological malignancies experiencing either relapse or graft failure (GF) after the first HCT. Data comparing outcomes of transplant strategies using either TCRαβ/CD19 depletion (TCRαβ) or post-transplant cyclophosphamide (PTCy) are currently lacking. This retrospective, multicentre study included children with haematological malignancies who received a second haplo-HCT, in which either TCRαβ depletion or PTCy was used as the graft-versus-host disease (GvHD) prophylaxis strategy. Primary outcomes included overall survival (OS), event-free survival (EFS), cumulative incidence of relapse (CIR) and non-relapse mortality (NRM). Overall, 123 patients were analysed, 56 receiving PTCy and 67 receiving TCRαβ. Median age at transplant was 9.1 years (range, 1.0-24.7 years). Relapse and GF were the transplant indications in 96 and 27 patients respectively. The 24-month OS [56.8% (95% CI: 42.5%-71.1%) vs. 43.2% (95% CI: 31.4%-55.1%)] and EFS [44.1% (95% CI: 30.3%-57.8%) vs. 35.8% (95% CI: 24.3%-47.3%)] did not differ between PTCy or TCRαβ cohorts. The CIR [34.0% (95% CI: 23.1%-50.1%) vs. 37.3% (95% CI: 27.3%-50.8%), p = 0.28] and NRM [18.9% (95% CI: 10.7%-33.4%) vs. 25.3% (95% CI: 16.8%-38.2%), p = 0.48] were comparable. Cumulative incidence of 100-day of any-grade acute GvHD was higher in the PTCy cohort [55.3% (95% CI: 43.7%-70.4%) vs. 32.8% (95% CI: 23.3%-46.2%), p = 0.02], with non-statistically significant differences for grade II-IV and grade III-IV. The 24-month cumulative incidence of chronic GvHD was higher in the PTCy cohort [38.8% (95% CI: 27.6%-54.6%) vs. 11.9% (95% CI: 6.2%-22.8%), p < 0.01], including moderate-severe forms [15.3% (95% CI: 8.1%-29.1%) vs. 1.4% (95% CI: 0.2%-10.4%), p < 0.01]. Infectious complications were comparable except for a higher adenovirus reactivation rate in the TCRαβ group (14.3% vs. 29.9%, p = 0.04). PTCy and TCRαβ offer comparable clinical outcomes in the setting of second haplo-HCT, although PTCy is associated with a higher incidence of GvHD and lower adenovirus reactivation.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Masetti R, Leardini D, Gottardi F, et al. Outcomes of children with haematological malignancies given second haploidentical haematopoietic stem cell transplantation with either TCRαβ/CD19 depletion or post-transplant cyclophosphamide. Br J Haematol. 2025. PMID: 40692189. doi:10.1111/bjh.70004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。